drugset / Press release
The Board of Aelis Farma decides to enter AEF0217 in preclinical development
2018-12-01 · Aelis Farma · original aelisfarma.com ↗
XXAEF0217 is being developed for the treatment of cognitive disorders and is expected to enter phase I trials at mid-2020.
The release as fetched from its publisher. aelisfarma.com ↗